By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- A new study on Biotechnology is now available. According to news reporting from Augusta, Georgia, by NewsRx journalists, research stated, "Lung cancer is still the leading cause of cancer-related deaths worldwide. Identifying new oncogenic drivers and developing efficient inhibitors through molecular targeting approaches are crucial for improving therapies."
The news correspondents obtained a quote from the research from Georgia Health Sciences University, "The aim of this study was to investigate whether targeting fibroblast growth factor receptor 1 (FGFR1) with ponatinib inhibits the cell growth in both established and primary lung cancer cells overexpressing FGFR1. Eighty-eight non-small cell lung cancer (NSCLC) and paired normal tissue specimens were analyzed by real-time RT-PCR for FGFR1 gene expression. We identified four cell lines and two newly established primary lung cancer cultures that showed high FGFR1 expression levels, and evaluated the effect of the novel FGFR1 inhibitor ponatinib on cell growth. Approximately 50% (30 out of 59) NSCLC specimens expressed FGFR1 >2-fold compared with their adjacent normal counterparts using quantitative RT-PCR. Ponatinib treatment of established NSCLC cell lines expressing higher levels of FGFR1 resulted in marked cell growth inhibition and suppression of clonogenicity. This growth inhibition was associated with inactivation of FGFR1 and its downstream targets. FGFR1 knockdown by shRNA achieved similar results when compared to treatment with ponatinib. Furthermore, ponatinib was able to significantly inhibit the growth of primary lung cancer cultures in vitro."
According to the news reporters, the research concluded: "Our data indicate that pharmacological inhibition of FGFR1 kinase activity with ponatinib may be effective for the treatment of lung cancer patients whose tumors overexpress FGFR1."
For more information on this research see: Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1. Oncology Reports, 2013;29(6):2181-90 (see also Biotechnology).
Our news journalists report that additional information may be obtained by contacting M. Ren, Cancer Center, Dept. of Medicine, Medical College of Georgia, Georgia Health Sciences University, Augusta, GA 30912, United States. Additional authors for this research include M. Hong, G. Liu, H. Wang, V. Patel, P. Biddinger, J. Silva, J. Cowell and Z. Hao.
Keywords for this news article include: Biotechnology, Augusta, Georgia, Oncology, Treatment, United States, Lung Neoplasms, Cancer Gene Therapy, North and Central America, Non Small Cell Lung Cancer.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC